The global intradermal injection market is expected to surpass an impressive valuation of US$ 3,878 Million in 2022 and is projected to exhibit a compound annual growth rate (CAGR) of 10.8% from 2022 to 2032.
In recent years, technological advancements have led to the development of surgical approaches with the aim to minimize waste and achieve better results. The reusable intradermal devices result in low waste generation, having a net positive effect on the productivity of an economy.
Along with this, the results of several meta-analyses prove that intradermal delivery of drugs reduces the intensity of adverse events. The factors mentioned above indicate the favorable condition for the rapid growth of this segment in the future.
| Report Attribute | Details |
|---|---|
| Expected Market Value (2022) | US$ 3,878 Million |
| Anticipated Forecast Value (2032) | US$ 10,814.47 Million |
| Projected Growth Rate (2022 to 2032) | 10.8% CAGR |
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
Over the past two decades, there has been an increase in the demand for intradermal injections. This is due to the rising incidence of diseases with a simultaneous increase in the use of intradermal vaccination and aesthetic procedures.
Furthermore, the growing burden of chronic diseases has led to a rise in the overall use of syringes, particularly disposable syringes, intradermal jet injectors, microinjections, and ballistic intradermal injection treatment and diagnostic purposes. The global demand for Intradermal Injections is projected to increase at a CAGR of 10.8% during the forecast period between 2022 and 2032, reaching a total of US$ 10,814.47 Million in 2032, according to a report from Future Market Insights (FMI). From 2017 to 2021, sales witnessed significant growth, registering a CAGR of 8%.
Growing Prevalence of Chronic Diseases, Increase in Aesthetic Surgical Procedures to Catalyse Intradermal Injection Uptake
The rising prevalence rate of tuberculosis is expected to promote the growth rate of the intradermal injection market. As per the data of WHO, tuberculosis is the 13th leading cause of death, and about 10 million cases of TB have been recorded every year, which resulted in a sudden rise in the diagnostic rate of TB during the last decade. This is one of the major factors that act as one of the leading reasons for increasing the intradermal injection market size of tuberculin syringes.
In addition to this, the number of aesthetic procedures is increasing rapidly in North America and Europe. The intradermal vaccination reduces the potential dose of antigens, improves the immune response, and decreases the anxiety associated with the vaccination. Moreover, aesthetic procedures are the leading segment of local aesthetic procedures, increasing the demand for intradermal injections.
Almost all vaccines require cold chain distribution and storage, which further limits resources or refrigerator space in a healthcare setting. Globally, approximately 17.4 million people are prone to rabies through animal bites annually. It occurs in more than 150 territories and countries, rabies is a viral disease that can cause encephalitis when transmitted to humans. Intradermal injections immensely help in lowering the cost of cell-derived vaccines for pre-exposure to rabies. The cost-savings with intradermal injections for rabies create immense opportunities for the intradermal injections market.
Principal Consultant
Unfavorable Government Provisions to Hinder Market Growth
Despite the advantages shown through various clinical studies, there are various barriers that hinder the usage of intradermal injections. The major world economies across Europe, the United States, and other developed regions rely on single-dose formats and have government funding or private insurance for vaccination. Emerging markets are anticipated to favor multi-dose formats and are limited by availability and cost of supply.
Increased Prevalence of Diseases to drive the adoption of intradermal Injection
According to the American Cancer Society’s 2022 report, over 1.9 million new cancers are expected to be recorded in the United States in 2022. Also, as per the same source, the risk of having cancer rises dramatically as one gets older, and in the United States, 80% of cancer patients are 55 or older, with 57% being 65 or older. These figures tell that the growing geriatric population is expected to have a significant positive impact on the growth of the market.
Not just this but according to the International Diabetes Federation’s report of December 2021, about 32.2 million people were living with diabetes in the United States in 2021, and this number is estimated to increase to 36.3 million by 2045. This expansion in the diabetes patient pool is expected to boost growth in intradermal injection in the United States.
The Increasing Prevalence of Diabetes is Spurring Demand for Intradermal Injection
As per the International Diabetes Federation (IDF) Diabetes Atlas 2021, the age-adjusted comparative prevalence of diabetes in the United Kingdom for 2021, 2030, and 2045 were estimated as 6.3%, 7.0%, and 7.5% respectively. Therefore, the gradual rise in the prevalence of diabetes is expected to increase the market demand.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
Normal Sized Needles to Lead the Method Type of Intradermal Injection
Based on the method, the intradermal injection market is segmented into normal-sized needles, short needles, and without needles. As per our research, normal-sized needles dominate the market, while the short-needle segment is estimated to register considerable growth.
Tuberculin Skin Test Segment is Estimated to Hold the Largest Share
Based on application, the market is segmented into tuberculin skin tests, allergy tests, local aesthetics, and others. The tuberculin skin test segment is estimated to hold the largest share of the market in 2022, accounting for 58% of total demand, while the local aesthetic segment is expected to register the highest CAGR during the forecast period.
Key players in the Intradermal Injection market are Becton Dickinson, Cardinal Health, West Pharmaceuticals Services, Terumo Corporation, Nanopass, Pharmajet, Idevax, Enusung, Crossject, and Hindustan Syringes and Medical Devices.
| Report Attribute | Details |
|---|---|
| Market Value in 2022 | US$ 3,878 Million |
| Market Value in 2032 | US$ 10,814.47 Million |
| Growth Rate | CAGR of 10.8% from 2022 to 2032 |
| Base Year for Estimation | 2021 |
| Historical Data | 2017 to 2021 |
| Forecast Period | 2022 to 2032 |
| Quantitative Units | Revenue in USD Billion and CAGR from 2022 to 2032 |
| Report Coverage | Revenue Forecast, Volume Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends, and Pricing Analysis |
| Segments Covered |
|
| Regions Covered |
|
| Key Countries Profiled |
|
| Key Companies Profiled |
|
| Customization | Available Upon Request |
FMI projects the global Intradermal Injection market to expand at a 10.8% value CAGR by 2032.
The global Intradermal Injection market is estimated at a market value of US$ 2.5 Billion.
The global Intradermal Injection market is expected to garner a market value of US$ 10814.47 Million.
FMI has projected North America to be one of the key regions for the Intradermal Injection market.
Becton Dickinson, Cardinal Health, West Pharmaceuticals services, Terumo Corporation, Nanopass, Pharmajet, Idevax, Enusung, Crossject, and Hindustan Syringes and Medical Devices.
1. Executive Summary 1.1. Global Market Outlook 1.2. Demand-side Trends 1.3. Supply-side Trends 1.4. Technology Roadmap Analysis 1.5. Analysis and Recommendations 2. Market Overview 2.1. Market Coverage / Taxonomy 2.2. Market Definition / Scope / Limitations 3. Market Background 3.1. Market Dynamics 3.1.1. Drivers 3.1.2. Restraints 3.1.3. Opportunity 3.1.4. Trends 3.2. Scenario Forecast 3.2.1. Demand in Optimistic Scenario 3.2.2. Demand in Likely Scenario 3.2.3. Demand in Conservative Scenario 3.3. Opportunity Map Analysis 3.4. Investment Feasibility Matrix 3.5. PESTLE and Porter’s Analysis 3.6. Regulatory Landscape 3.6.1. By Key Regions 3.6.2. By Key Countries 3.7. Regional Parent Market Outlook 4. Global Market Analysis 2017 to 2021 and Forecast, 2022 to 2032 4.1. Historical Market Size Value (US$ million) Analysis, 2017 to 2021 4.2. Current and Future Market Size Value (US$ million) Projections, 2022 to 2032 4.2.1. Y-o-Y Growth Trend Analysis 4.2.2. Absolute $ Opportunity Analysis 5. Global Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By Method 5.1. Introduction / Key Findings 5.2. Historical Market Size Value (US$ million) Analysis By Method, 2017 to 2021 5.3. Current and Future Market Size Value (US$ million) Analysis and Forecast By Method, 2022 to 2032 5.3.1. Normal Sized Needles 5.3.2. Short Needle 5.3.2.1. Intradermal Microinjection 5.3.2.2. Microneedle Arrays 5.3.2.3. Tattoo Devices 5.3.3. Without Needle 5.3.3.1. Intradermal Liquid Jet Devices 5.3.3.2. Ballistic Intradermal Injectors 5.4. Y-o-Y Growth Trend Analysis By Method, 2017 to 2021 5.5. Absolute $ Opportunity Analysis By Method, 2022 to 2032 6. Global Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By Application 6.1. Introduction / Key Findings 6.2. Historical Market Size Value (US$ million) Analysis By Application, 2017 to 2021 6.3. Current and Future Market Size Value (US$ million) Analysis and Forecast By Application, 2022 to 2032 6.3.1. Tuberculin Skin Test 6.3.2. Allergy Test 6.3.3. Local Aesthetics 6.3.4. Others 6.4. Y-o-Y Growth Trend Analysis By Application, 2017 to 2021 6.5. Absolute $ Opportunity Analysis By Application, 2022 to 2032 7. Global Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By End User 7.1. Introduction / Key Findings 7.2. Historical Market Size Value (US$ million) Analysis By End User, 2017 to 2021 7.3. Current and Future Market Size Value (US$ million) Analysis and Forecast By End User, 2022 to 2032 7.3.1. Hospitals 7.3.2. Diagnostic Laboratories 7.3.3. Academics And Research Institutes 7.3.4. Others 7.4. Y-o-Y Growth Trend Analysis By End User, 2017 to 2021 7.5. Absolute $ Opportunity Analysis By End User, 2022 to 2032 8. Global Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By Region 8.1. Introduction 8.2. Historical Market Size Value (US$ million) Analysis By Region, 2017 to 2021 8.3. Current Market Size Value (US$ million) Analysis and Forecast By Region, 2022 to 2032 8.3.1. North America 8.3.2. Latin America 8.3.3. Europe 8.3.4. South Asia 8.3.5. East Asia 8.3.6. Oceania 8.3.7. Middle East and Africa (MEA) 8.4. Market Attractiveness Analysis By Region 9. North America Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By Country 9.1. Historical Market Size Value (US$ million) Trend Analysis By Market Taxonomy, 2017 to 2021 9.2. Market Size Value (US$ million) Forecast By Market Taxonomy, 2022 to 2032 9.2.1. By Country 9.2.1.1. The USA 9.2.1.2. Canada 9.2.2. By Method 9.2.3. By Application 9.2.4. By End User 9.3. Market Attractiveness Analysis 9.3.1. By Country 9.3.2. By Method 9.3.3. By Application 9.3.4. By End User 9.4. Key Takeaways 10. Latin America Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By Country 10.1. Historical Market Size Value (US$ million) Trend Analysis By Market Taxonomy, 2017 to 2021 10.2. Market Size Value (US$ million) Forecast By Market Taxonomy, 2022 to 2032 10.2.1. By Country 10.2.1.1. Brazil 10.2.1.2. Mexico 10.2.1.3. Rest of Latin America 10.2.2. By Method 10.2.3. By Application 10.2.4. By End User 10.3. Market Attractiveness Analysis 10.3.1. By Country 10.3.2. By Method 10.3.3. By Application 10.3.4. By End User 10.4. Key Takeaways 11. Europe Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By Country 11.1. Historical Market Size Value (US$ million) Trend Analysis By Market Taxonomy, 2017 to 2021 11.2. Market Size Value (US$ million) Forecast By Market Taxonomy, 2022 to 2032 11.2.1. By Country 11.2.1.1. Germany 11.2.1.2. United Kingdom 11.2.1.3. France 11.2.1.4. Spain 11.2.1.5. Italy 11.2.1.6. Rest of Europe 11.2.2. By Method 11.2.3. By Application 11.2.4. By End User 11.3. Market Attractiveness Analysis 11.3.1. By Country 11.3.2. By Method 11.3.3. By Application 11.3.4. By End User 11.4. Key Takeaways 12. South Asia Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By Country 12.1. Historical Market Size Value (US$ million) Trend Analysis By Market Taxonomy, 2017 to 2021 12.2. Market Size Value (US$ million) Forecast By Market Taxonomy, 2022 to 2032 12.2.1. By Country 12.2.1.1. India 12.2.1.2. Malaysia 12.2.1.3. Singapore 12.2.1.4. Thailand 12.2.1.5. Rest of South Asia 12.2.2. By Method 12.2.3. By Application 12.2.4. By End User 12.3. Market Attractiveness Analysis 12.3.1. By Country 12.3.2. By Method 12.3.3. By Application 12.3.4. By End User 12.4. Key Takeaways 13. East Asia Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By Country 13.1. Historical Market Size Value (US$ million) Trend Analysis By Market Taxonomy, 2017 to 2021 13.2. Market Size Value (US$ million) Forecast By Market Taxonomy, 2022 to 2032 13.2.1. By Country 13.2.1.1. China 13.2.1.2. Japan 13.2.1.3. South Korea 13.2.2. By Method 13.2.3. By Application 13.2.4. By End User 13.3. Market Attractiveness Analysis 13.3.1. By Country 13.3.2. By Method 13.3.3. By Application 13.3.4. By End User 13.4. Key Takeaways 14. Oceania Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By Country 14.1. Historical Market Size Value (US$ million) Trend Analysis By Market Taxonomy, 2017 to 2021 14.2. Market Size Value (US$ million) Forecast By Market Taxonomy, 2022 to 2032 14.2.1. By Country 14.2.1.1. Australia 14.2.1.2. New Zealand 14.2.2. By Method 14.2.3. By Application 14.2.4. By End User 14.3. Market Attractiveness Analysis 14.3.1. By Country 14.3.2. By Method 14.3.3. By Application 14.3.4. By End User 14.4. Key Takeaways 15. MEA Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By Country 15.1. Historical Market Size Value (US$ million) Trend Analysis By Market Taxonomy, 2017 to 2021 15.2. Market Size Value (US$ million) Forecast By Market Taxonomy, 2022 to 2032 15.2.1. By Country 15.2.1.1. GCC Countries 15.2.1.2. South Africa 15.2.1.3. Israel 15.2.1.4. Rest of MEA 15.2.2. By Method 15.2.3. By Application 15.2.4. By End User 15.3. Market Attractiveness Analysis 15.3.1. By Country 15.3.2. By Method 15.3.3. By Application 15.3.4. By End User 15.4. Key Takeaways 16. Key Countries Market Analysis 16.1. The USA 16.1.1. Pricing Analysis 16.1.2. Market Share Analysis, 2021 16.1.2.1. By Method 16.1.2.2. By Application 16.1.2.3. By End User 16.2. Canada 16.2.1. Pricing Analysis 16.2.2. Market Share Analysis, 2021 16.2.2.1. By Method 16.2.2.2. By Application 16.2.2.3. By End User 16.3. Brazil 16.3.1. Pricing Analysis 16.3.2. Market Share Analysis, 2021 16.3.2.1. By Method 16.3.2.2. By Application 16.3.2.3. By End User 16.4. Mexico 16.4.1. Pricing Analysis 16.4.2. Market Share Analysis, 2021 16.4.2.1. By Method 16.4.2.2. By Application 16.4.2.3. By End User 16.5. Germany 16.5.1. Pricing Analysis 16.5.2. Market Share Analysis, 2021 16.5.2.1. By Method 16.5.2.2. By Application 16.5.2.3. By End User 16.6. The United Kingdom 16.6.1. Pricing Analysis 16.6.2. Market Share Analysis, 2021 16.6.2.1. By Method 16.6.2.2. By Application 16.6.2.3. By End User 16.7. France 16.7.1. Pricing Analysis 16.7.2. Market Share Analysis, 2021 16.7.2.1. By Method 16.7.2.2. By Application 16.7.2.3. By End User 16.8. Spain 16.8.1. Pricing Analysis 16.8.2. Market Share Analysis, 2021 16.8.2.1. By Method 16.8.2.2. By Application 16.8.2.3. By End User 16.9. Italy 16.9.1. Pricing Analysis 16.9.2. Market Share Analysis, 2021 16.9.2.1. By Method 16.9.2.2. By Application 16.9.2.3. By End User 16.10. India 16.10.1. Pricing Analysis 16.10.2. Market Share Analysis, 2021 16.10.2.1. By Method 16.10.2.2. By Application 16.10.2.3. By End User 16.11. Malaysia 16.11.1. Pricing Analysis 16.11.2. Market Share Analysis, 2021 16.11.2.1. By Method 16.11.2.2. By Application 16.11.2.3. By End User 16.12. Singapore 16.12.1. Pricing Analysis 16.12.2. Market Share Analysis, 2021 16.12.2.1. By Method 16.12.2.2. By Application 16.12.2.3. By End User 16.13. Thailand 16.13.1. Pricing Analysis 16.13.2. Market Share Analysis, 2021 16.13.2.1. By Method 16.13.2.2. By Application 16.13.2.3. By End User 16.14. China 16.14.1. Pricing Analysis 16.14.2. Market Share Analysis, 2021 16.14.2.1. By Method 16.14.2.2. By Application 16.14.2.3. By End User 16.15. Japan 16.15.1. Pricing Analysis 16.15.2. Market Share Analysis, 2021 16.15.2.1. By Method 16.15.2.2. By Application 16.15.2.3. By End User 16.16. South Korea 16.16.1. Pricing Analysis 16.16.2. Market Share Analysis, 2021 16.16.2.1. By Method 16.16.2.2. By Application 16.16.2.3. By End User 16.17. Australia 16.17.1. Pricing Analysis 16.17.2. Market Share Analysis, 2021 16.17.2.1. By Method 16.17.2.2. By Application 16.17.2.3. By End User 16.18. New Zealand 16.18.1. Pricing Analysis 16.18.2. Market Share Analysis, 2021 16.18.2.1. By Method 16.18.2.2. By Application 16.18.2.3. By End User 16.19. GCC Countries 16.19.1. Pricing Analysis 16.19.2. Market Share Analysis, 2021 16.19.2.1. By Method 16.19.2.2. By Application 16.19.2.3. By End User 16.20. South Africa 16.20.1. Pricing Analysis 16.20.2. Market Share Analysis, 2021 16.20.2.1. By Method 16.20.2.2. By Application 16.20.2.3. By End User 16.21. Israel 16.21.1. Pricing Analysis 16.21.2. Market Share Analysis, 2021 16.21.2.1. By Method 16.21.2.2. By Application 16.21.2.3. By End User 17. Market Structure Analysis 17.1. Competition Dashboard 17.2. Competition Benchmarking 17.3. Market Share Analysis of Top Players 17.3.1. By Regional 17.3.2. By Method 17.3.3. By Application 17.3.4. By End User 18. Competition Analysis 18.1. Competition Deep Dive 18.1.1. Becton Dickinson 18.1.1.1. Overview 18.1.1.2. Product Portfolio 18.1.1.3. Profitability by Market Segments 18.1.1.4. Sales Footprint 18.1.1.5. Strategy Overview 18.1.1.5.1. Marketing Strategy 18.1.2. Cardinal Health 18.1.2.1. Overview 18.1.2.2. Product Portfolio 18.1.2.3. Profitability by Market Segments 18.1.2.4. Sales Footprint 18.1.2.5. Strategy Overview 18.1.2.5.1. Marketing Strategy 18.1.3. West Pharmaceuticals services 18.1.3.1. Overview 18.1.3.2. Product Portfolio 18.1.3.3. Profitability by Market Segments 18.1.3.4. Sales Footprint 18.1.3.5. Strategy Overview 18.1.3.5.1. Marketing Strategy 18.1.4. Terumo Corporation 18.1.4.1. Overview 18.1.4.2. Product Portfolio 18.1.4.3. Profitability by Market Segments 18.1.4.4. Sales Footprint 18.1.4.5. Strategy Overview 18.1.4.5.1. Marketing Strategy 18.1.5. Nanopass 18.1.5.1. Overview 18.1.5.2. Product Portfolio 18.1.5.3. Profitability by Market Segments 18.1.5.4. Sales Footprint 18.1.5.5. Strategy Overview 18.1.5.5.1. Marketing Strategy 18.1.6. Pharmajet 18.1.6.1. Overview 18.1.6.2. Product Portfolio 18.1.6.3. Profitability by Market Segments 18.1.6.4. Sales Footprint 18.1.6.5. Strategy Overview 18.1.6.5.1. Marketing Strategy 18.1.7. Idevax 18.1.7.1. Overview 18.1.7.2. Product Portfolio 18.1.7.3. Profitability by Market Segments 18.1.7.4. Sales Footprint 18.1.7.5. Strategy Overview 18.1.7.5.1. Marketing Strategy 18.1.8. Enusung 18.1.8.1. Overview 18.1.8.2. Product Portfolio 18.1.8.3. Profitability by Market Segments 18.1.8.4. Sales Footprint 18.1.8.5. Strategy Overview 18.1.8.5.1. Marketing Strategy 18.1.9. Crossject 18.1.9.1. Overview 18.1.9.2. Product Portfolio 18.1.9.3. Profitability by Market Segments 18.1.9.4. Sales Footprint 18.1.9.5. Strategy Overview 18.1.9.5.1. Marketing Strategy 18.1.10. Hindustan Syringes 18.1.10.1. Overview 18.1.10.2. Product Portfolio 18.1.10.3. Profitability by Market Segments 18.1.10.4. Sales Footprint 18.1.10.5. Strategy Overview 18.1.10.5.1. Marketing Strategy 19. Assumptions & Acronyms Used 20. Research Methodology
Explore Healthcare Insights
View Reports
Intradermal Injection Market
